Julie K. Andersen, PhD, Professor

Targeting cell death in Parkinson's disease: identification of novel therapeutics

As a renowned expert on Parkinson’s disease, Dr. Andersen is pursuing a wide array of leads toward treatments for this complex neurodegenerative disorder. She has identified several early risk signals for Parkinson’s, an age-related illness that causes a progressive decline in movement and muscle control. The symptoms can include shaking hands and difficulty with walking.  

Amongst the early risk signals identified by Dr. Andersen are elevated levels of iron and declining amounts of a protective antioxidant called glutathione. Recently, the Andersen lab has also discovered valuable clues by examining the roles of enzymes and other proteins involved in nerve cell degeneration. Normally, proteins carry out the routine work inside cells. But some enzymes can promote the symptoms of Parkinson’s disease. Blocking those enzymes might slow down the disease. Other therapies might result from the opposite tactic:  reinforcing the work of different enzymes that guard against Parkinson’s disease. These enzymes seem to prevent damage to genes that protect the nervous system.

The Andersen lab is also involved in identifying potential biomarkers for Parkinson’s that may allow early interventional therapy.

Dr. Andersen was born in Great Falls, Montana. She earned a doctorate in Neuromolecular Biology at the University of California, Los Angeles (UCLA). She completed a postdoctoral fellowship at Harvard Medical School and Massachusetts General Hospital before going to the University of Southern California as an assistant then an associate professor at the Andrus Gerontology Center. She joined the Buck Institute in 2000.

Media Expertise
Dr. Andersen welcomes media inquiries on the following subjects:
Parkinson’s disease, risk factors: genetic and environmental; therapeutics.

Phone: 415-209-2070
Administrative Lab Coordinator: Shelly Jennings
Phone: 415-209-2002

“My greatest hope is that our work here at the Buck will allow us to diagnose Parkinson's at the earliest possible stage, so treatment can begin before the disease has a chance to progress.   That would free patients to live fulfilling lives without major disability.’’ 

- Julie K. Andersen, PhD


Recent Publications


Carol A Lazzara, Rebeccah R Riley... Yong-Hwan Kim "The combination of lithium and L-dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: Relevance for Parkinson's disease therapy." Brain Res. 1622 127-136
Almas Siddiqui, Dipa Bhaumik... Julie K Andersen "Mitochondrial Quality Control via the PGC1α-TFEB Signaling Pathway Is Compromised by Parkin Q311X Mutation But Independently Restored by Rapamycin." J. Neurosci. 35:37 12833-44
Change text size: